https://vettapharma.com/pharmaceutical-news/pharma-giant-merck-nears-28bn-32bn-negotiations-for-revolution-medicines/ 2026-01-20T09:48:28+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/are-weight-loss-medications-a-temporary-fix/ 2026-01-20T09:43:10+00:00 hourly 1.0 https://vettapharma.com/whats-new-in-artificial-intelligence/wiley-issues-guidelines-for-responsible-use-of-ai-in-scholarly-writing/ 2026-01-20T09:46:51+00:00 hourly 1.0 https://vettapharma.com/whats-new-in-artificial-intelligence/nvidia-and-eli-lilly-launch-ai-co-innovation-lab-to-transform-drug-discovery/ 2026-01-20T10:37:38+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/medical-device-correction-issued-for-millions-of-abbott-freestyle-libre-3-and-3-plus-sensors-in-us/ 2026-01-20T09:43:31+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/prenatal-factors-linked-to-adult-onset-multiple-sclerosis-risk/ 2026-01-20T09:42:47+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-zycubo-first-ever-treatment-for-menkes-disease-in-children/ 2026-01-20T09:49:38+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/chinas-national-medical-products-administration-approves-sanofis-myqorzo-and-redemplo/ 2026-01-21T06:18:52+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-for-sjogrens-disease/ 2026-01-20T09:43:59+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/teva-announces-positive-ajovy-results-in-children-and-adolescents-with-episodic-migraine-space-trial/ 2026-01-20T09:47:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/abelzeta-sells-remaining-china-rights-as-astrazeneca-takes-global-control-of-c-car031-in-630-million-deal/ 2026-01-20T09:37:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ziihera-tevimbra-combination-shows-survival-advantage-in-first-line-her2-advanced-gea/ 2026-01-22T15:06:07+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-removes-suicidal-warning-for-glp-1-drugs/ 2026-01-20T09:42:24+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/teva-announces-positive-ajovy-results-in-children-and-adolescents-with-episodic-migraine-space-trial-2/ 2026-01-19T12:30:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/abelzeta-sells-remaining-china-rights-as-astrazeneca-takes-global-control-of-c-car031-in-630-million-deal-2/ 2026-01-19T13:30:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sun-pharma-brings-unloxcyt-to-u-s-for-advanced-cutaneous-squamous-cell-carcinoma/ 2026-01-20T10:14:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ziihera-tevimbra-combination-shows-survival-advantage-in-first-line-her2-advanced-gea-2/ 2026-01-19T15:30:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-removes-suicidal-warning-for-glp-1-drugs-2/ 2026-01-19T17:30:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sun-pharma-brings-unloxcyt-to-u-s-for-advanced-cutaneous-squamous-cell-carcinoma-2/ 2026-01-19T18:52:00+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/jjs-new-clinical-data-highlights-caplyta-promise-for-depression-remission/ 2026-01-21T05:30:25+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/are-you-looking-for-reliable-pharma/ 2026-01-20T11:09:34+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/are-you-looking-for-reliable-pharma-385/ 2026-01-20T11:13:32+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/jjs-new-clinical-data-highlights-caplyta-promise-for-depression-remission-2/ 2026-01-20T12:00:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsk-acquires-rapt-therapeutics-for-food-allergy-treatment/ 2026-01-20T14:46:40+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/is-sun-pharma-on-a-buying-spree-in-the-us/ 2026-01-21T07:55:42+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsk-pfizer-and-shionogi-restructure-viiv-healthcare-stake/ 2026-01-20T18:34:01+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/breaking-news-astrazeneca-acquires-modella-ai/ 2026-01-21T07:06:11+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsk-acquires-rapt-therapeutics-for-food-allergy-treatment-2/ 2026-01-20T19:46:37+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/is-sun-pharma-on-a-buying-spree-in-the-us-2/ 2026-01-20T23:16:37+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsk-pfizer-and-shionogi-restructure-viiv-healthcare-stake-2/ 2026-01-20T23:33:57+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/breaking-news-astrazeneca-acquires-modella-ai-2/ 2026-01-21T00:33:57+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/moderna-and-merck-announce-strong-5-year-melanoma-vaccine-results/ 2026-01-21T08:13:41+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/moderna-and-merck-announce-strong-5-year-melanoma-vaccine-results-2/ 2026-01-21T13:13:37+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/americans-deserve-reliable-information-on-food-ingredients-says-fda/ 2026-01-22T06:58:19+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofis-amlitelimab-shows-promise-for-atopic-dermatitis-treatment/ 2026-01-23T10:54:47+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/china-nmpa-clears-trelegy-ellipta-as-first-triple-therapy-for-asthma-and-copd/ 2026-01-24T16:32:01+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/while-cruz-blamed-trump-india-and-the-eu/ 2026-01-27T06:49:44+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsks-arexvy-vaccine-approved-for-all-adults-in-eu/ 2026-01-28T07:42:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-updates-zilbrysq-labeling-for-patient-safety/ 2026-01-29T09:31:15+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-darzalex-faspro-for-multiple-myeloma-treatment/ 2026-01-29T10:02:55+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/700x-strategic-shift-astrazenecas-china-bet-questions-pharmas-faith-in-india-post-eu-deal/ 2026-01-29T10:42:58+00:00 hourly 1.0 https://vettapharma.com/whats-new-in-artificial-intelligence/aidoc-gains-fda-approval-for-innovative-ai-triage-solution/ 2026-01-29T11:37:28+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazeneca-partners-with-cspc-to-innovate-obesity-treatments/ 2026-01-30T09:22:51+00:00 hourly 1.0 https://vettapharma.com/whats-new-in-artificial-intelligence/bristol-myers-squibb-joins-microsoft-ai-in-lung-cancer-detection/ 2026-01-30T11:00:02+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazenecas-imfinzi-gains-chmp-support-for-gastric-cancer/ 2026-02-02T17:55:38+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-grants-fast-track-designation-to-journavx-new-non-opioid-pain-relief-option/ 2026-02-02T08:31:19+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/eli-lilly-to-invest-3-5-billion-in-pennsylvania-injectable-manufacturing-facility/ 2026-02-02T08:49:10+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-launches-precheck-pilot-to-boost-us-pharmaceutical-manufacturing/ 2026-02-02T08:03:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/tonix-pharmaceuticals-reveals-promising-tonmya-phase-3-trial-data/ 2026-02-02T09:08:17+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-exits-bangladesh/ 2026-02-02T09:33:24+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/constipation-in-diabetes-the-role-of-glp-1-based-therapies/ 2026-02-02T10:56:44+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/glp-1-medications-transforming-cardiovascular-care/ 2026-02-03T13:51:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-grants-priority-review-for-datroway-in-breast-cancer-treatment/ 2026-02-06T08:37:13+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/simcere-and-boehringer-ingelheim-new-ibd-treatment-alliance/ 2026-02-06T09:07:39+00:00 hourly 1.0 https://vettapharma.com/whats-new-in-artificial-intelligence/ge-healthcare-partners-with-diagnoly-for-ai-powered-ultrasound/ 2026-02-06T09:27:01+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/emd-serono-leverages-trumprx-gov-to-advance-national-access-to-ivf-treatments/ 2026-02-08T16:50:07+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-plans-enforcement-action-against-non-fda-approved-glp-1-drugs/ 2026-02-08T17:06:27+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/can-the-liver-glp-1r-agonism-unlock-the-next-leap-in-weight-loss-therapy/ 2026-02-08T17:58:36+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fenebrutinib-shows-potential-as-first-investigational-therapy-to-reduce-disability-progression-in-ppms-says-roche/ 2026-02-10T08:41:40+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/takeda-secures-fda-priority-review-for-oveporexton-nda-in-narcolepsy-type-1/ 2026-02-10T08:59:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsks-arexvy-receives-china-cde-review-for-preventing-rsv-lower-respiratory-disease-in-older-adults/ 2026-02-10T09:24:19+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/are-glp-1-drugs-quietly-rewriting-what-we-buy-at-the-grocery-store/ 2026-02-10T10:38:11+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofis-rilzabrutinib-gains-fda-breakthrough-and-japanese-orphan-designations-for-warm-autoimmune-hemolytic-anemia/ 2026-02-12T08:48:13+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofi-ousts-paul-hudson-names-belen-garijo-as-new-ceo-in-leadership-shift/ 2026-02-12T09:00:48+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-keytruda-and-keytruda-qlex-with-paclitaxel-%c2%b1-bevacizumab-for-pd-l1-cps-%e2%89%a5-1-platinum-resistant-ovarian-cancer/ 2026-02-12T09:17:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-alerts-junebar-recall-allergy-alert-for-undeclared-milk-and-soy/ 2026-02-13T07:03:18+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/triple-therapy-breztri-improves-lung-function-in-phase-iii-asthma-trials-astrazeneca-reports/ 2026-02-13T07:13:48+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-optune-pax-a-breakthrough-for-pancreatic-cancer/ 2026-02-13T07:30:59+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-vanrafia-eases-kidney-decline-in-iga-nephropathy/ 2026-02-13T07:56:16+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/moderna-in-trouble-again-fda-rejects-mrna-1010-flu-shot-submission/ 2026-02-13T08:26:32+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/csl-showcases-stable-leadership-as-pharma-industry-sees-ceo-shake-ups-including-sanofis-executive-overhaul/ 2026-02-13T12:16:54+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/legal-battle-novo-nordisk-vs-hims-hers-on-compounded-medications/ 2026-02-14T08:55:54+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/small-but-mighty-alnylams-bold-2030-growth-targets-eclipse-big-pharma-giant-astrazenecas-forecasts/ 2026-02-14T09:17:21+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/bridgebios-infigratinib-trial-shows-promise-for-achondroplasia/ 2026-02-14T09:49:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/eli-lilly-acquires-orna-therapeutics-for-2-4-billion-deal-expanding-push-into-in-vivo-car-t-therapies/ 2026-02-14T10:21:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/roches-gazyva-shows-promise-for-primary-membranous-nephropathy/ 2026-02-16T07:33:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/beyfortus-reduces-rsv-hospitalizations-sanofis-new-study-findings-unveiled/ 2026-02-16T08:03:14+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ema-endorses-ucbs-kygevvi-hope-for-rare-thymidine-kinase-deficiency/ 2026-02-16T08:28:09+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/natco-ones-again-this-time-wins-indias-cdsco-approval-for-generic-semaglutide/ 2026-02-16T11:31:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/trumprx-launch-access-discounted-prescription-drug-prices-today/ 2026-02-16T12:48:04+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsks-exdensur-eu-approves-innovative-treatment-for-severe-asthma-and-chronic-nasal-polyps/ 2026-02-17T09:31:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/roches-pharma-rd-gets-new-leadership-amid-industry-wide-ceo-shake-ups-following-sanofi-and-csl-transitions/ 2026-02-17T09:52:43+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/india-becomes-ground-zero-in-global-pharma-talent-war-as-sanofi-expands-hyderabad-and-rivals-ramp-up-billion-dollar-innovation-bets/ 2026-02-17T10:50:56+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-remibrutinib-becomes-first-therapy-to-meet-phase-iii-primary-endpoint-in-chronic-inducible-urticaria/ 2026-02-18T09:51:43+00:00 hourly 1.0 https://vettapharma.com/whats-new-in-artificial-intelligence/meta-and-nvidia-join-forces-to-revolutionize-ai-infrastructure/ 2026-02-18T10:07:58+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/deciphera-pharmaceuticals-tirabrutinib-nda-accepted-by-u-s-fda/ 2026-02-18T10:27:27+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofi-and-teva-report-promising-long-term-data-for-duvakitug-in-ibd/ 2026-02-18T10:40:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/modernas-mrna-1010-flu-vaccine-re-accepted-for-fda-review-signaling-turnaround-after-earlier-rejection/ 2026-02-19T08:27:41+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/bioasia-india-2026-hyderabads-25b-pharma-investment-surge/ 2026-02-19T09:11:24+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/viivs-long-acting-cabenuva-outperforms-daily-oral-art-in-hiv-patients-with-adherence-challenges-phase-iii-data-published-in-nejm/ 2026-02-19T09:48:21+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-warns-public-do-not-eat-or-sell-raw-oysters-from-british-columbia-due-to-norovirus-risk/ 2026-02-19T10:21:14+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/eli-lillys-taltz-and-zepbound-combo-shows-superior-efficacy-in-psoriasis-and-obesity-clinical-trial/ 2026-02-19T14:00:43+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/eli-lillys-retevmo-game-changer-in-early-stage-lung-cancer/ 2026-02-19T14:26:05+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/regenerons-garetosmab-fda-priority-review-for-fop-treatment/ 2026-02-19T15:45:07+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/us-fda-accepts-roches-giredestrant-nda-for-esr1-mutated-er-positive-advanced-breast-cancer/ 2026-02-20T07:23:14+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/omvoh-delivers-durable-3-year-steroid-free-remission-in-crohns-disease-patients-with-90-maintaining-durable-control-in-phase-3-vivid-2-study/ 2026-02-20T07:41:32+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/mercks-enflonsia-shows-promising-rsv-protection-for-kids/ 2026-02-20T07:59:54+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/takeda-reports-sustained-pediatric-entyvio-efficacy-with-strong-one-year-remission-rates/ 2026-02-20T10:55:57+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/insmed-reports-2025-financial-results-guides-strong-2026-revenues-with-growth/ 2026-02-20T12:03:15+00:00 hourly 1.0 https://vettapharma.com/whats-new-in-artificial-intelligence/eu-ai-act-brings-real-compliance-implications-for-organizations-and-audit-teams/ 2026-02-20T12:16:16+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/nhs-galleri-trial-reveals-clinically-meaningful-cancer-detection-improvements-despite-mixed-primary-results/ 2026-02-20T12:25:06+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/nhs-galleri-trial-shows-early-detection-gains-reduced-late-stage-cancer-diagnoses/ 2026-02-20T14:04:38+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-fixed-duration-calquence-combo-for-first-line-cll-and-sll/ 2026-02-20T14:16:22+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-to-divest-india-listed-unit-continue-commercial-and-rd-presence/ 2026-02-20T17:39:32+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/daiichi-sankyo-names-ex-syncona-ex-novartis-leader-john-tsai-global-head-of-rd/ 2026-02-20T17:57:07+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/grail-shares-plunge-after-large-nhs-galleri-cancer-screening-trial-misses-primary-goal/ 2026-02-20T18:17:48+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-first-all-oral-fixed-duration-venclexta-combination-for-untreated-cll-patients/ 2026-02-21T09:07:20+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/can-repurposed-medicines-and-vaccines-change-the-course-of-alzheimers-disease/ 2026-02-21T09:56:29+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/supreme-court-strikes-down-trumps-global-tariffs-easing-some-trade-pressures-mixed-signals-for-pharma-sector/ 2026-02-21T16:31:33+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-to-present-expanded-rhapsido-remibrutinib-data-at-aaaai-2026/ 2026-02-23T07:50:36+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/moderna-to-present-at-td-cowen-and-barclays-2026-conferences/ 2026-02-23T07:55:56+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-bysanti-for-bipolar-i-disorder-and-schizophrenia-treatment/ 2026-02-23T08:22:14+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/who-confirms-libya-eliminates-trachoma-as-public-health-problem-in-2026/ 2026-02-23T08:35:46+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-accepts-tevas-nda-for-once-monthly-olanzapine-injectable-for-schizophrenia/ 2026-02-23T08:50:05+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/the-unstoppable-trump-moves-swiftly-with-10-global-tariff-after-supreme-court-blocks-emergency-duties/ 2026-02-23T09:06:46+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/moonlakes-sonelokimab-shows-clinically-meaningful-benefit-in-phase-2-axspa-trial/ 2026-02-23T09:23:25+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lilly-launches-zepbound-multi-dose-kwikpen-for-monthly-obesity-treatment-nationwide/ 2026-02-24T07:55:48+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-unveils-framework-to-fast-track-individualized-therapy-development-for-ultra-rare-diseases/ 2026-02-24T08:10:18+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/merck-united-states-separates-human-health-operations-into-oncology-and-specialty-units/ 2026-02-24T12:23:07+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/tectonic-therapeutic-inc-appoints-proven-biotech-dealmaker-francois-nader-as-board-chair/ 2026-02-24T09:33:04+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-reported-new-real-world-data-showing-longer-pfs-with-pluvicto-before-chemotherapy-in-mcrpc/ 2026-02-24T12:50:16+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/earlier-eli-lilly-now-abbvie-expand-u-s-pharmaceutical-manufacturing/ 2026-02-24T13:41:33+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofi-and-regenerons-dupixent-receives-first-fda-approval-for-allergic-fungal-rhinosinusitis/ 2026-02-24T17:14:11+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/biocon-gains-u-s-fda-approval-for-glp-1-liraglutide-weight-management-drug-market/ 2026-02-25T06:47:01+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsk-to-acquire-35pharma-for-950m-strategic-move-in-biotech/ 2026-02-25T10:54:37+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/grail-and-amgen-to-present-at-46th-annual-td-cowen-health-care-conference/ 2026-02-25T12:14:31+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-accepts-dr-reddys-biologics-license-application-for-interchangeable-abatacept-biosimilar/ 2026-02-25T13:56:04+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-to-build-radioligand-therapy-site-in-denton-texas/ 2026-02-25T14:44:35+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/zydus-lifesciences-plans-day-one-india-launch-of-innovative-semaglutide-injection-therapy/ 2026-02-25T15:06:26+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-grants-full-approval-to-pfizers-braftovi-combination-regimen-for-metastatic-colorectal-cancer/ 2026-02-25T15:25:52+00:00 hourly 1.0 https://vettapharma.com/subscribe/subscribe-to-the-vettapharma-newsletter-for-the-latest-pharmaceutical-news-research-insights-and-ai-driven-advancements-write-to-us-at-subscribevettapharma-com/ 2026-02-25T16:13:46+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsks-linerixibat-nda-accepted-for-priority-review-in-china-for-cholestatic-pruritus/ 2026-02-26T08:08:23+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsks-bepirovirsen-nda-accepted-for-regulatory-review-in-japan-for-chronic-hepatitis-b/ 2026-02-26T08:25:17+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/mercks-numelvi-fda-approves-jak-inhibitor-for-dog-itching/ 2026-02-26T09:16:09+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/vanda-pharmaceuticals-imsidolimab-biologics-license-application-accepted-by-fda/ 2026-02-26T09:34:05+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/merck-phase-3-data-shows-doravirine-islatravir-maintains-hiv-suppression-effectively/ 2026-02-26T08:40:04+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofi-india-q4-2025-profit-soars-50-dividend-increased/ 2026-02-26T13:25:36+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lupin-limited-no-1-globally-in-pharma-sustainability-rankings-2025/ 2026-02-26T13:52:13+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofi-regenerons-dupixent-approved-in-japan-as-first-targeted-therapy-for-bullous-pemphigoid/ 2026-03-24T08:20:06+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lilly-secures-fda-approval-for-oral-glp-1-orforglipron-weight-loss-pill/ 2026-04-06T05:46:07+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazeneca-imfinzi-imjudo-combo-improves-pfs-in-early-liver-cancer-patients/ 2026-04-06T06:17:02+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsk-exdensur-depemokimab-approved-in-china-for-crswnp-ultra-long-acting-biologic-therapy/ 2026-04-09T05:02:08+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofis-lunsekimig-shows-promise-in-respiratory-disease-trials/ 2026-04-09T10:46:57+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-foundayo-lillys-new-game-changer-for-obesity-treatment/ 2026-04-09T11:05:05+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazeneca-selling-last-india-manufacturing-plant-signaling-major-global-strategy-shift/ 2026-04-10T05:05:51+00:00 hourly 1.0 https://vettapharma.com/whats-new-in-artificial-intelligence/merck-google-cloud-partnership-accelerates-enterprise-ai-to-transform-drug-development-globally/ 2026-04-28T09:02:20+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazenecas-breztri-aerosphere-approved-for-asthma-treatment/ 2026-04-28T09:51:21+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsks-bepirovirsen-for-chronic-hepatitis-b-fda-review-update/ 2026-04-28T10:01:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-rhapsido-first-oral-therapy-for-chronic-urticaria/ 2026-04-28T10:45:15+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/eli-lilly-to-acquire-ajax-therapeutics-what-it-means-for-oncology/ 2026-04-28T11:50:49+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofis-tolebrutinib-recommended-for-secondary-progressive-multiple-sclerosis-treatment-approval/ 2026-04-28T12:25:41+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazeneca-q1-2026-revenue-surpasses-15-billion-driven-by-strong-growth/ 2026-04-29T06:55:22+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-q1-2026-performance-driven-by-growth-brands-pipeline-and-strategic-focus/ 2026-04-29T07:21:00+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/csl-showcases-stable-leadership-as-pharma-industry-sees-ceo-shake-ups-including-sanofis-executive-overhaul-2/ 2026-04-30T06:37:31+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-infant-formula-testing-confirms-safety-with-over-300-samples-analyzed/ 2026-04-30T06:48:13+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsk-q1-2026-results-7-6b-turnover-and-core-profit-growth/ 2026-04-30T07:03:52+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/can-targeting-multiple-toxic-proteins-finally-shift-alzheimers-treatment-outcomes/ 2026-04-30T07:42:44+00:00 hourly 1.0 https://vettapharma.com/subscribe/subscribe-to-the-vettapharma-newsletter-for-the-latest-pharmaceutical-news-research-insights-and-ai-driven-advancements-write-to-us-at-subscribevettapharma-com-2/ 2026-06-01T06:31:56+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/eli-lilly-reports-19-8-billion-q1-revenue-surge-in-2026/ 2026-05-04T08:09:31+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-expands-us-manufacturing-with-23-billion-investment/ 2026-05-04T08:35:45+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/amgens-300m-investment-boosts-u-s-manufacturing-capacity/ 2026-05-05T07:57:44+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofi-enters-new-growth-era-as-belen-garijo-takes-charge-globally/ 2026-05-05T10:22:21+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lupin-receives-fda-approval-for-glycerol-phenylbutyrate-liquid/ 2026-05-06T07:13:27+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lilly-omvoh-il-23p19-data-shows-durable-remission-in-inflammatory-bowel-disease-patients/ 2026-05-06T07:20:38+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-launches-halo-ai-artificial-intelligence-platform-streamlining-regulatory-processes/ 2026-05-07T14:28:31+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/2253/ 2026-05-07T14:41:49+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-launches-new-radioligand-therapy-facility-in-texas/ 2026-05-08T12:46:08+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/eli-lilly-invests-4-5b-in-indiana-for-advanced-medicine-production/ 2026-05-08T12:59:06+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/angelini-pharma-acquires-catalyst-for-4-1-billion/ 2026-05-08T13:22:28+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/bristol-myers-squibbs-sotyktu-approved-for-active-psoriatic-arthritis-in-europe/ 2026-05-09T05:56:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-bizengri-for-nrg1-fusion-positive-cancer/ 2026-05-11T09:34:47+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsk-partners-with-sbp-group-for-bepirovirsen-in-china/ 2026-05-11T09:47:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/biocon-pharma-receives-canada-approval-for-micafungin-injection/ 2026-05-11T09:58:59+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ucb-joins-forces-with-cancer-research-uk-for-cancer-therapies/ 2026-05-11T10:10:27+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-leo-pharmas-anzupgo-cream-potential-pediatric-approval-insights/ 2026-05-18T05:35:06+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-pluvicto-data-shows-58-lower-psa-progression-risk-in-prostate-cancer/ 2026-05-18T05:42:52+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazenecas-enhertu-gains-fda-approval-for-early-breast-cancer/ 2026-05-18T05:49:12+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-astrazenecas-baxfendy-as-first-aldosterone-synthase-inhibitor-for-adult-hypertension-management-in-us/ 2026-05-18T06:16:19+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-showcases-advances-in-cancer-therapy-at-asco-2026/ 2026-05-22T05:18:25+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lilly-asco-2026-presentations-highlight-oncology-pipeline-advances-across-multiple-tumor-types/ 2026-05-22T05:32:29+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gilead-expands-oncology-and-global-health-strategy-through-acquisition-partnership-and-financing-initiatives/ 2026-05-22T05:44:11+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gilead-and-kite-unveil-new-oncology-data-at-asco-2026/ 2026-05-22T05:52:15+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazenecas-datroway-approved-in-us-for-1st-line-tnbc-extends-overall-survival-benefit/ 2026-05-25T07:25:27+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazenecas-enhertu-recommended-by-chmp-for-her2-positive-solid-tumours-high-response-rates/ 2026-05-25T07:30:48+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sun-pharma-q4fy26-sales-rs145598mn-up-13-6-yoy-net-profit-rises-26-2/ 2026-05-25T07:35:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazenecas-key-findings-at-asco-2026-innovations-in-oncology/ 2026-05-25T07:47:58+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazenecas-camizestrant-plus-cdk4-6-reduces-progression-risk-56-in-esr1-mutant-breast-cancer/ 2026-05-25T07:48:07+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gileads-hepcludex-gains-fda-approval-for-chronic-hepatitis-d-showing-48-response/ 2026-05-27T08:38:14+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ema-cvmp-backs-multiple-veterinary-vaccines-and-updates-including-librela-adverse-events/ 2026-05-25T07:55:46+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/abbvies-maviret-recommended-by-chmp-for-acute-hepatitis-c-with-96-svr12/ 2026-05-25T07:59:27+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ema-accepts-tevas-maa-for-olanzapine-lai-tev-749-for-adult-schizophrenia-treatment/ 2026-05-25T08:05:33+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ucbs-bimzelx-shows-superior-acr50-versus-skyrizi-in-psoriatic-arthritis-week-16/ 2026-05-25T08:13:21+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lillys-foundayo-shows-up-to-13-weight-loss-in-older-adults-65/ 2026-05-25T08:20:05+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/takeda-updates-amitiza-antitrust-jury-verdict-and-revises-fiscal-2025-financial-results/ 2026-05-26T07:55:12+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/mercks-precem-tct-begins-phase-3-for-metastatic-colorectal-cancer-1020-patients-planned/ 2026-05-25T08:28:14+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lilly-verve-102-base-editor-reduced-ldl-cholesterol-62-after-single-infusion-treatment/ 2026-05-26T07:50:36+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-reveals-innovative-kidney-disease-data-at-era-2026/ 2026-05-26T07:56:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/mercks-precem-tct-begins-phase-3-for-metastatic-colorectal-cancer-1020-patients-planned-2/ 2026-05-26T08:01:23+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/takeda-updates-amitiza-antitrust-jury-verdict-and-revises-fiscal-2025-financial-results-2/ 2026-05-26T08:02:47+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-extends-astrazeneca-camizestrant-breast-cancer-review-delaying-anticipated-approval-decision/ 2026-05-27T11:36:49+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/roche-launches-ai-powered-liver-disease-panel-targeting-billions-with-chronic-liver-conditions/ 2026-05-27T11:37:25+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ema-backs-first-oral-glp-1-wegovy-treatment-for-obesity-and-weight-management-globally/ 2026-05-27T11:53:43+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/regeneron-otarmenitmgene-ema-filing-advances-gene-therapy-for-hearing-loss-treatment-in-children/ 2026-05-27T12:17:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/regeneron-lynozyfic-rapid-myeloma-responses-strengthen-bispecific-antibody-treatment-potential-in-heavily-treated-patients/ 2026-05-27T12:17:56+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/the-growing-impact-of-rare-diseases-on-pharma-revenue-growth/ 2026-05-28T07:15:01+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-grants-priority-review-for-sanofis-venglustat-in-gaucher-rare-disease/ 2026-05-28T08:24:47+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/global-pharma-leaders-urge-japan-investment-reforms-amid-life-sciences-competitiveness-concerns/ 2026-05-29T08:01:37+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-astrazenecas-imfinzi-for-high-risk-nmibc-key-insights/ 2026-05-29T07:02:39+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/who-prioritizes-maftivimab-for-bundibugyo-ebola-trials/ 2026-05-29T07:14:34+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/gsks-bepirovirsen-achieves-unprecedented-cure-rates-in-hbv-patients/ 2026-05-29T07:20:12+00:00 hourly 1.0 https://vettapharma.com/featured-scientific-stories/xpro1595-phase-ii-trial-tackling-neuroinflammation-in-alzheimers/ 2026-05-29T11:28:47+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-grants-priority-review-for-zyduss-saroglitazar-in-primary-biliary-cholangitis-treatment/ 2026-05-29T07:43:37+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/daiichi-sankyo-asco-oncology-updates-strengthen-adc-portfolio-expansion-across-multiple-cancers/ 2026-05-29T07:48:35+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/cvs-restores-zepbound-coverage-as-lilly-expands-obesity-market-access-significantly/ 2026-05-29T08:11:31+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/novartis-to-showcase-immunology-advances-at-eular-2026-congress/ 2026-06-01T10:07:37+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/pluvicto-strengthens-case-for-earlier-use-in-advanced-prostate-cancer/ 2026-06-01T09:56:38+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/roche-obesity-pipeline-advances-as-petrelintide-and-enicepatide-enter-phase-iii/ 2026-06-01T10:10:33+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/lillys-selpercatinib-cuts-lung-cancer-recurrence-by-83-in-study/ 2026-06-01T10:21:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/modernas-asco-presentations-highlight-personalized-cancer-vaccine-and-multiple-myeloma-programs/ 2026-06-01T10:26:48+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-proposes-streamlined-animal-testing-for-oncology-drugs/ 2026-06-01T12:54:39+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-wockhardts-first-in-class-zaynich-opening-9-billion-resistant-infection-market/ 2026-06-01T12:54:42+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/astrazenecas-emerald-3-breakthrough-in-liver-cancer-treatment/ 2026-06-01T12:54:49+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/pfizers-braftovi-regimen-nearly-doubles-progression-free-survival-in-metastatic-colorectal-cancer/ 2026-06-01T13:22:20+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/incytes-tafasitamab-shows-improved-outcomes-in-dlbcl-at-asco/ 2026-06-01T13:19:28+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/incytes-tafasitamab-shows-improved-outcomes-in-dlbcl-at-asco-2/ 2026-06-01T13:21:52+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/pfizers-braftovi-regimen-nearly-doubles-progression-free-survival-in-metastatic-colorectal-cancer-2/ 2026-06-01T13:23:20+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/asco-data-show-novartis-scemblix-sustains-long-term-efficacy-in-chronic-myeloid-leukemia/ 2026-06-02T10:06:51+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-priority-review-puts-roches-giredestrant-on-track-to-transform-early-breast-cancer/ 2026-06-02T10:11:11+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/moderna-and-cepi-collaborate-to-develop-ebolavirus-vaccine/ 2026-06-02T10:27:43+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/european-commission-approves-amgens-imdylltra-following-40-survival-advantage-in-sclc/ 2026-06-02T10:29:42+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-mannkinds-afrezza-expanding-needle-free-mealtime-insulin-access-for-children/ 2026-06-02T12:04:37+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofi-expands-accelrare-platform-with-biogen-to-speed-rare-disease-diagnosis/ 2026-06-03T16:23:40+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/amgen-to-present-new-uplizna-and-tavneos-data-at-eular-2026/ 2026-06-03T16:23:44+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ema-and-ama-join-forces-to-combat-bundibugyo-ebola-outbreak/ 2026-06-03T16:23:50+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/mannkind-advances-nintedanib-dpi-trials-for-idiopathic-pulmonary-fibrosis/ 2026-06-03T16:26:34+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/asco-data-show-astrazenecas-emerald-3-trial-marks-breakthrough-in-unresectable-liver-cancer/ 2026-06-04T08:33:12+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/asco-data-show-astrazenecas-camizestrant-delayed-cancer-progression-in-serena-6/ 2026-06-04T08:39:02+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/sanofi-launches-action-2026-employee-share-purchase-plan/ 2026-06-04T08:52:15+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/ucb-dapirolizumab-pegol-promising-results-in-lupus-treatment-at-eular-2026/ 2026-06-04T09:03:46+00:00 hourly 1.0 https://vettapharma.com/pharmaceutical-news/fda-approves-natco-and-lupins-eribulin-injection-targeting-43-7-million-u-s-market/ 2026-06-04T09:12:24+00:00 hourly 1.0